Drug Delivery Outsourcing In A World Of Pharma’s Shifting Sands
Executive Summary
The contract drug delivery industry is facing disruptive influences from an evolving client base, the increase in biologics manufacturing and specialty pharma needs. In Vivo speaks to Catalent’s vice president of strategy, Cornell Stamoran, about the evolution of the industry and the continuous search for efficiency.
You may also be interested in...
Ways To Find And Nurture Young, Diverse Talent In Pharma
On this podcast, In Vivo's Jo Shorthouse is joined by Rebekah Martin, senior vice president of reward, inclusion, and talent acquisition at AstraZeneca to talk about the ways that pharma should be encouraging a diverse and inclusive team of young talent, and that strong connection between diversity of thought and innovation.
Insmed CEO On Innovating To Compete In Rare Disease
Leading the company with the only therapy approved for NTM lung disease, Will Lewis tells In Vivo that success comes from giving researchers room to breath, visualizing patient benefit, and sailing into uncharted waters.
Spotting Zebras: Technology Cutting Through The Diagnostic Odyssey
In Vivo talked to two organizations making progress in the diagnosis of rare diseases using software and genomic sequencing.